Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(14)
•••
Comment by Lookingforclueson Aug 19, 2020 12:35pm
231 Views
Post# 31428989

RE:RE:RE:RE:RE:RE:RE:RE:RE:Hiring Stern

RE:RE:RE:RE:RE:RE:RE:RE:RE:Hiring Stern
themagicbox wrote: Here is someone who doesnt know how to compare things.

And that fact that you call the phase 2 data a "fiasco" and concluding stern's (yet to be) marketing campaign for ATE, to already be hinted at in the chicago press demonstrates: poor crtitical analysis, mind reading, unqualified certainty, and you havent done your due diligience.   

You sound just like that other dip "lookingforclues(less)". Same song, different handle. Except you dont have the same hardon for MUGs.
Blazesb wrote: Who do you trust on Covid 19:  Donald Trump or Dr. Anthony Fauci?

Who do you trust on Antibe phase 2 data: Dan Legault or Dr. Wallace?

Stern gave a hint to the answer with Dr. Wallace's editorial in the Chicago press.  It'll be interesting to watch them pursue this line. Burnish Dr. Wallace and eventually address the phase 2 data fiasco. 

That's the only path forward for Antibe. 



[HARD......ON ......SUCH AN AWFUL WORD TO BE USED IN PUBLIC.
 

Yup...everyone do the Due Dilligence!  Very important when insiders sell a few weeks ago for approx 40% more than current price!
Nothing against Mugs, he is just a dummy mouthpiece..... except he is the voice of.......guess who!
No prizes here.  Too simple!

 

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities